Researcher.Life Logo

Zhongguo shi yan xue ye xue za zhi / Zhongguo bing li sheng li xue hui = Journal of experimental hematology / Chinese Association of Pathophysiology : Impact Factor & More

pISSN: 1009-2137
Recommended pre-submission checks
Powered by Paperpal by Editage

Zhongguo shi yan xue ye xue za zhi / Zhongguo bing li sheng li xue hui = Journal of experimental hematology / Chinese Association of Pathophysiology Journal Specifications

Indexed in the following public directories

  • Scopus Scopus
Overview
Publisher Haidian-qu

Planning to publish in Zhongguo shi yan xue ye xue za zhi / Zhongguo bing li sheng li xue hui = Journal of experimental hematology / Chinese Association of Pathophysiology ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Zhongguo shi yan xue ye xue za zhi / Zhongguo bing li sheng li xue hui = Journal of experimental hematology / Chinese Association of Pathophysiology

Clinical Study on the Transition of First-Line Bortezomib Intole- rance to Carfilzomib in the Treatment of Multiple Myeloma
  • 1 Feb 2026
  • Zhongguo shi yan xue ye xue za zhi
Analysis of Test Results of Anti-HCV Reagents in Blood Screening Laboratory
  • 1 Feb 2026
  • Zhongguo shi yan xue ye xue za zhi
Clinical Characteristics and Prognostic Analysis of Patients with EBV-Positive Diffuse Large B-Cell Lymphoma
  • 1 Feb 2026
  • Zhongguo shi yan xue ye xue za zhi
Analysis of Factors Contributing to Apheresis Platelet Aggregation
  • 1 Feb 2026
  • Zhongguo shi yan xue ye xue za zhi
Cause Analysis of HLA-B Allele Missed Detection Based on AlltypeTM FastplexTM Next Generation Sequencing
  • 1 Feb 2026
  • Zhongguo shi yan xue ye xue za zhi
The Clinical Value of Plasma cfTFEB and miR-1246 in Predicting the Efficacy of Bortezomib Treatment for Patients with Multiple Myeloma
  • 1 Feb 2026
  • Zhongguo shi yan xue ye xue za zhi
Clinical Study on the Transition of First-Line Bortezomib Intole- rance to Carfilzomib in the Treatment of Multiple Myeloma
  • 1 Feb 2026
  • Zhongguo shi yan xue ye xue za zhi
Analysis of Test Results of Anti-HCV Reagents in Blood Screening Laboratory
  • 1 Feb 2026
  • Zhongguo shi yan xue ye xue za zhi
Clinical Characteristics and Prognostic Analysis of Patients with EBV-Positive Diffuse Large B-Cell Lymphoma
  • 1 Feb 2026
  • Zhongguo shi yan xue ye xue za zhi
Analysis of Factors Contributing to Apheresis Platelet Aggregation
  • 1 Feb 2026
  • Zhongguo shi yan xue ye xue za zhi
Cause Analysis of HLA-B Allele Missed Detection Based on AlltypeTM FastplexTM Next Generation Sequencing
  • 1 Feb 2026
  • Zhongguo shi yan xue ye xue za zhi
The Clinical Value of Plasma cfTFEB and miR-1246 in Predicting the Efficacy of Bortezomib Treatment for Patients with Multiple Myeloma
  • 1 Feb 2026
  • Zhongguo shi yan xue ye xue za zhi

FAQs on Zhongguo shi yan xue ye xue za zhi / Zhongguo bing li sheng li xue hui = Journal of experimental hematology / Chinese Association of Pathophysiology